TipRanks
Advertisement
Advertisement
Analyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability
PremiumRatingsAnalyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability
3M ago
Kalaris Therapeutics reports positive Phase 1a TH103 results
Premium
Company Announcements
Kalaris Therapeutics reports positive Phase 1a TH103 results
3M ago
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
Premium
The Fly
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
3M ago
CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
PremiumMarket NewsCRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks
5M ago
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
5M ago
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
Premium
The Fly
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
5M ago
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe FlyKalaris Therapeutics initiated with an Overweight at Morgan Stanley
6M ago
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
Premium
Company Announcements
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
6M ago
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
Premium
Ratings
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―